8-K: CCRN Sets Annual Meeting Date, Contingent on Aya Merger

Cross Country Healthcare, Inc. announced its 2025 Annual Meeting of Stockholders for December 9, 2025, contingent on the completion of its merger with Aya Healthcare, Inc. in Q4 2025.

Summary

• The 2025 Annual Meeting of Stockholders is scheduled for December 9, 2025, which is more than 30 days after the anniversary of the 2024 Annual Meeting.
• The Annual Meeting will only take place if the pending merger transaction with Aya Healthcare, Inc. (the Aya Merger) is not completed prior to December 9, 2025.
• The company continues to expect that the Aya Merger will be completed in the fourth quarter of 2025.
• If the Aya Merger is completed before the Annual Meeting, the meeting will not occur, and any director candidates or stockholder proposals submitted will not be considered.
• The proxy statement for the Annual Meeting, including time and website address for the virtual-only meeting, will be made available to stockholders prior to or on October 30, 2025.
• The deadline for stockholder proposals to be eligible for inclusion in the company's proxy statement (pursuant to Rule 14a-8) is the close of business on October 10, 2025.
• The deadline for stockholders to propose business or nominate directors (in accordance with the company's Bylaws) is October 10, 2025.
• Stockholders intending to solicit proxies for director nominees other than the company's nominees must provide notice (as required by Rule 14a-19) by October 10, 2025.

Sentiment

Score: 6

Explanation: The filing provides clarity on the conditional annual meeting schedule and deadlines, while reiterating the expectation for the Aya Merger to close in Q4 2025, which is generally positive for merger-related news. However, the conditional nature of the meeting introduces some uncertainty for shareholder participation.

Positives

• Clear communication of the conditional annual meeting schedule and associated deadlines to shareholders.
• Reiteration of the expectation for the Aya Merger to close in the fourth quarter of 2025, providing an update on the merger's anticipated timeline.

Negatives

• The conditional nature of the Annual Meeting introduces uncertainty for shareholders regarding their ability to participate in corporate governance through proposals or director nominations.
• Stockholder proposals and director nominations may become moot if the Aya Merger completes before the scheduled Annual Meeting date.

Risks

• Uncertainty regarding the actual occurrence of the 2025 Annual Meeting of Stockholders due to its contingency on the completion of the Aya Merger.
• Risk that stockholder proposals and director nominations submitted by the October 10, 2025 deadline will not be considered if the Aya Merger closes prior to December 9, 2025.

Future Outlook

The company continues to expect that the Aya Merger will be completed in the fourth quarter of 2025.

Management Comments

• We continue to expect that the Aya Merger will be completed in the fourth quarter of 2025.

Industry Context

This filing primarily addresses corporate governance matters and the procedural implications of a pending merger within the healthcare staffing industry. The anticipated completion of the Aya Merger in Q4 2025 suggests ongoing consolidation trends in the sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Will need to monitor the Aya Merger completion status to determine if the Annual Meeting will occur and if their proposals/nominations will be considered. Provides clarity on deadlines for participation if the meeting proceeds.
• Management/Board: Must manage the merger process while also preparing for a conditional annual meeting and ensuring compliance with all related regulatory deadlines.

Next Steps

• Completion of the Aya Merger in the fourth quarter of 2025.
• Making the proxy statement for the Annual Meeting available to stockholders by October 30, 2025.
• Stockholders submitting proposals or nominations by October 10, 2025, if they wish to participate in the conditional Annual Meeting.

Key Dates

Recommendation

The filing primarily provides procedural updates regarding the company's annual meeting, which is contingent on the expected completion of the Aya Healthcare merger in Q4 2025. It does not contain new financial performance data or significant strategic shifts that would alter the fundamental investment thesis. Investors are likely awaiting the merger's finalization, making a 'hold' recommendation appropriate as the current news reinforces the existing merger timeline without introducing new catalysts for significant price movement.

Keywords

Cross Country Healthcare, CCRN, Aya Healthcare, Merger, Annual Meeting, Stockholder Meeting, Proxy Statement, Corporate Governance, SEC Filing, 8-K, Director Nominations, Stockholder Proposals